Photo taken from Vivek Subbiah/LinkedIn
Aug 25, 2023, 16:32
Vivek Subbiah: Huge win for patients with RET+ thyroid cancers.
Quoting Vivek Subbiah, the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, on Twitter/X:
“Huge win for patients with RET+ thyroid cancers. Selpercatinib demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer. Super thrilled and excited for all all RET+ patients globally. Knew that this baby would graduate with honors right from the 1st patient dosed.
Have you heard about Lazarus effect? Yes, this was the 1st ever RET+ Thyroid cancer patient dosed on the drug. Our clinic team witnessed 1st hand the power of precision medicine.
1. First RET+ patient story Annals of Oncology
sciencedirect.com/science/articl
2. NEJM paper
nejm.org/doi/pdf/10.105
3. Press release Loxo Oncology
investor.lilly.com/news-releases/
Source: Vivek Subbiah/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46